SW083688
Based on 1 Customer Validation
SW083688 is a selective TAOK2 inhibitor with an IC50 of 1.3 μM. SW083688 increases the abundance of p62 protein, inhibits autophagosome maturation, and blocks Autophagic flux. SW083688 is applicable for the research of non-small cell lung cancer and pancreatic cancer.
For research use only. We do not sell to patients.
- Purity: 99.78%
- CAS No.: 422281-45-6
- Formula: C23H25N3O5S
- Molecular Weight:455.53
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Cancer Compound Library
HY-L025
-
Autophagy Compound Library
HY-L029
-
Anti-Lung Cancer Compound Library
HY-L075
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Highly Selective Inhibitors Library
HY-L158
-
Highly Selective Activators Library
HY-L159
-
Cell Death Library
HY-L162
-
Mitophagy Compound Library
HY-L180
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Anti-Brain Cancer Compound Library
HY-L188
-
High-Throughput Bioactive Compound Library
HY-L205
Biological Activity
TAOK 2 (IC50 of 1.3 μM)[1]
SW083688 inhibits TAOK2 activity in both cell-free and cell-based in vitro systems, suppresses autophagy by increasing p62 levels and, together with SW034538, impairing MAP1LC3A/B processing, and supports TAOK2's positive role in autophagy[1].
SW083688 is highly specific for TAOK2, with significant inhibition only of TAOK2 across a panel of 45 kinases[2].
SW083688 inhibits purified TAOK2 kinase activity with an IC50 of 1.3 μM in a radiometric assay[2].
SW083688 (50 μM; 24 h) significantly impairs autophagic flux in U2OS cells stably expressing GFP-LC3, as shown by increased GFP-LC3 accumulation and p62 protein abundance[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:U2OS cells stably expressing GFP-LC3
-
Concentration:50 μM
-
Incubation Time:24 h
-
Result:Increased GFP-LC3 accumulation (normalized median fluorescence value significantly higher than DMSO control).
Increased p62 protein abundance, both indicators of impaired autophagic flux.
Chemical Information
-
CAS No. 422281-45-6
-
Appearance Solid
-
Molecular Weight 455.53
-
Formula C23H25N3O5S
-
Color White to off-white
-
SMILES
O=C(C1=CC(NC(N2CCCOCC)=S)=C(C=C1)C2=O)NCC3OC4=CC=CC=C4OC3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
DMSO : 100 mg/mL (219.52 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.49 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (271 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Ye J, et al. Research Advances in the Molecular Functions and Relevant Diseases of TAOKs, Novel STE20 Kinase Family Members. Curr Pharm Des. 2020;26(26):3122-3133. [Content Brief]
[2]. Piala AT, et al. Discovery of novel TAOK2 inhibitor scaffolds from high-throughput screening. Bioorg Med Chem Lett. 2016;26(16):3923-3927. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.1952 mL | 10.9762 mL | 21.9525 mL | 54.8811 mL |
| 5 mM | 0.4390 mL | 2.1952 mL | 4.3905 mL | 10.9762 mL | |
| 10 mM | 0.2195 mL | 1.0976 mL | 2.1952 mL | 5.4881 mL | |
| 15 mM | 0.1463 mL | 0.7317 mL | 1.4635 mL | 3.6587 mL | |
| 20 mM | 0.1098 mL | 0.5488 mL | 1.0976 mL | 2.7441 mL | |
| 25 mM | 0.0878 mL | 0.4390 mL | 0.8781 mL | 2.1952 mL | |
| 30 mM | 0.0732 mL | 0.3659 mL | 0.7317 mL | 1.8294 mL | |
| 40 mM | 0.0549 mL | 0.2744 mL | 0.5488 mL | 1.3720 mL | |
| 50 mM | 0.0439 mL | 0.2195 mL | 0.4390 mL | 1.0976 mL | |
| 60 mM | 0.0366 mL | 0.1829 mL | 0.3659 mL | 0.9147 mL | |
| 80 mM | 0.0274 mL | 0.1372 mL | 0.2744 mL | 0.6860 mL | |
| 100 mM | 0.0220 mL | 0.1098 mL | 0.2195 mL | 0.5488 mL |
Powered by Bioz